European Alliance for Personalised Medicine (EAPM) shared a post on LinkedIn:
“Insight from EAPM’s Side Event at ESMO – Berlin, October 18, 2025
Liquid biopsy, MRD assessment, and digital pathology are reshaping clinical trials – enabling remote monitoring, real-time insights, and more inclusive participation. Underserved enrollment has increased by up to 40%, while timelines are improving.
But challenges remain: fragmented digital pathology infrastructure, limited reimbursement in many regions, and inconsistent validation standards for ctDNA and MRD.
Speaking during the session, Luca Mazzarella (IEO European Institute of Oncology) noted: ‘The focus shouldn’t be on how impressive the technology is, but on the benefit it brings to patients.’
As these technologies advance, it will be essential to ensure they translate into clearer pathways, fair access, and tangible improvements in patient outcomes – rather than innovation for innovation’s sake.”
Proceed to the video attached to the post.
More posts featuring EAPM.